Skip to main content
Top
Published in: Diabetes Therapy 3/2018

Open Access 01-06-2018 | Original Research

Is a Previously or Currently Reduced Testosterone Level in Male Patients with Type 2 Diabetes Mellitus a Risk Factor for the Development of Coronary Artery Disease? A Systematic Review and Meta-analysis

Author: Feng Huang

Published in: Diabetes Therapy | Issue 3/2018

Login to get access

Abstract

Introduction

We aimed to systematically investigate the association between testosterone level and cardiovascular risk in male patients with type 2 diabetes mellitus (T2DM) by comparing male T2DM patients with low testosterone levels to male T2DM patients with normal testosterone levels at baseline in terms of the number of cases of coronary artery disease (CAD).

Methods

Online databases were carefully searched for studies relating to testosterone, diabetes mellitus, and cardiovascular risk by using the search terms ‘testosterone,’ ‘diabetes mellitus,’ and ‘coronary artery/cardiovascular disease.’ The only endpoint in this analysis was CAD/atherosclerosis/coronary plaque/major adverse coronary event prior to or following testosterone reduction at baseline. The analytical parameters used in this analysis were the risk ratio (RR) with the 95% confidence interval (CI), as obtained using the RevMan 5.3 software.

Results

3467 male patients with T2DM (1079 patients with a low testosterone level versus 2388 patients with a normal testosterone level) were included. The results of this analysis showed that when a random effects model was used, a higher risk of CAD/cardiovascular disease was observed in diabetic patients with a low testosterone level than in those with a normal testosterone level (RR 1.24, 95% CI 0.94–1.63; P = 0.13). However, the difference in risk was not statistically significant. Similarly, with a fixed effects model, a low testosterone level was associated with a higher CAD/cardiovascular risk of disease (RR 1.12, 95% CI 0.98–1.34; P = 0.08); in this case, the difference in risk between the T2DM patients with low and normal testosterone levels approached statistical significance.

Conclusion

A previously or currently reduced testosterone level was not found to be statistically significantly associated with a high risk of CAD/cardiovascular disease in male patients with T2DM. However, the difference in risk between the T2DM patients with low and normal testosterone levels was observed to approach statistical significance.
Literature
1.
go back to reference Tan KH, Barr ELM, Koshkina V, Ma S, Kowlessur S, Magliano DJ, Söderberg S, Chia KS, Zimmet P, Lim WY. Diabetes mellitus prevalence is increasing in South Asians but is stable in Chinese living in Singapore and Mauritius. J Diabetes. 2017;9(9):855–64. Tan KH, Barr ELM, Koshkina V, Ma S, Kowlessur S, Magliano DJ, Söderberg S, Chia KS, Zimmet P, Lim WY. Diabetes mellitus prevalence is increasing in South Asians but is stable in Chinese living in Singapore and Mauritius. J Diabetes. 2017;9(9):855–64.
2.
go back to reference Islam GM. The risk of developing cardiovascular disease in Bangladesh: does diabetes mellitus matter? Which socioeconomic status does it impact? A cross sectional study. J Am Soc Hypertens. 2017;11(1):45–53.e1. Islam GM. The risk of developing cardiovascular disease in Bangladesh: does diabetes mellitus matter? Which socioeconomic status does it impact? A cross sectional study. J Am Soc Hypertens. 2017;11(1):45–53.e1.
3.
go back to reference Tambo A, Roshan MH, Pace NP. Testosterone and cardiovascular disease. Open Cardiovasc Med J. 2016;15(10):1–10.CrossRef Tambo A, Roshan MH, Pace NP. Testosterone and cardiovascular disease. Open Cardiovasc Med J. 2016;15(10):1–10.CrossRef
4.
go back to reference Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl. 2009;32(6):587–98.CrossRef Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl. 2009;32(6):587–98.CrossRef
5.
go back to reference Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef
6.
go back to reference Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRef Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRef
8.
go back to reference Farias JM, Tinetti M, Khoury M, Umpierrez GE. Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(12):4698–703.CrossRef Farias JM, Tinetti M, Khoury M, Umpierrez GE. Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(12):4698–703.CrossRef
9.
go back to reference Gianatti EJ, Hoermann R, Lam Q, Dupuis P, Zajac JD, Grossmann M. Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes. Clin Endocrinol (Oxf). 2016;84(1):55–62.CrossRef Gianatti EJ, Hoermann R, Lam Q, Dupuis P, Zajac JD, Grossmann M. Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes. Clin Endocrinol (Oxf). 2016;84(1):55–62.CrossRef
10.
go back to reference Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Pract. 2016;70(3):244–53.CrossRef Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Pract. 2016;70(3):244–53.CrossRef
11.
go back to reference Liu RT, Chung MS, Wang PW, Chen CD, Lee JJ, Lee WC, Chancellor MB, Yang KD, Chuang YC. The prevalence and predictors of androgen deficiency in Taiwanese men with type 2 diabetes. Urology. 2013;82(1):124–9.CrossRef Liu RT, Chung MS, Wang PW, Chen CD, Lee JJ, Lee WC, Chancellor MB, Yang KD, Chuang YC. The prevalence and predictors of androgen deficiency in Taiwanese men with type 2 diabetes. Urology. 2013;82(1):124–9.CrossRef
12.
go back to reference Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–33.CrossRef Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–33.CrossRef
13.
go back to reference Hou JW, Collins DC, Schleicher RL. Sources of cholesterol for testosterone biosynthesis in murine Leydig cells. Endocrinology. 1990;127(5):2047–55.CrossRef Hou JW, Collins DC, Schleicher RL. Sources of cholesterol for testosterone biosynthesis in murine Leydig cells. Endocrinology. 1990;127(5):2047–55.CrossRef
14.
go back to reference Zouboulis CC, Degitz K. Androgen action on human skin—from basic research to clinical significance. Exp Dermatol. 2004;13(Suppl 4):5–10.CrossRef Zouboulis CC, Degitz K. Androgen action on human skin—from basic research to clinical significance. Exp Dermatol. 2004;13(Suppl 4):5–10.CrossRef
15.
go back to reference Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2(6):e000272.CrossRef Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2(6):e000272.CrossRef
16.
go back to reference Ammar EM, Said SA, Hassan MS. Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res. 2004;50(3):253–9.CrossRef Ammar EM, Said SA, Hassan MS. Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res. 2004;50(3):253–9.CrossRef
17.
go back to reference Herring MJ, Oskui PM, Hale SL, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc. 2013;2(4):e000271.CrossRef Herring MJ, Oskui PM, Hale SL, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc. 2013;2(4):e000271.CrossRef
18.
go back to reference Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210(1):232–6.CrossRef Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210(1):232–6.CrossRef
19.
go back to reference Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol. 1997;146(8):609–17.CrossRef Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol. 1997;146(8):609–17.CrossRef
20.
go back to reference Lim TS, Yun JS, Cha SA, Song KH, Yoo KD, Ahn YB, Park YM, Ko SH. Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. Korean J Intern Med. 2016;31(6):1110–9.CrossRef Lim TS, Yun JS, Cha SA, Song KH, Yoo KD, Ahn YB, Park YM, Ko SH. Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. Korean J Intern Med. 2016;31(6):1110–9.CrossRef
21.
go back to reference Donner DG, Elliott GE, Beck BR, Bulmer AC, Du Toit EF. Impact of diet-induced obesity and testosterone deficiency on the cardiovascular system: a novel rodent model representative of males with testosterone-deficient metabolic syndrome (TDMetS). PLoS One. 2015;10(9):e0138019.CrossRef Donner DG, Elliott GE, Beck BR, Bulmer AC, Du Toit EF. Impact of diet-induced obesity and testosterone deficiency on the cardiovascular system: a novel rodent model representative of males with testosterone-deficient metabolic syndrome (TDMetS). PLoS One. 2015;10(9):e0138019.CrossRef
22.
go back to reference Daka B, Langer RD, Larsson CA, Rosén T, Jansson PA, Råstam L, Lindblad U. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord. 2015;25(15):35.CrossRef Daka B, Langer RD, Larsson CA, Rosén T, Jansson PA, Råstam L, Lindblad U. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord. 2015;25(15):35.CrossRef
23.
go back to reference Hernández-Mijares A, García-Malpartida K, Solá-Izquierdo E, Bañuls C, Rocha M, Gómez-Martínez MJ, Mármol R, Víctor VM. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med. 2010;7(5):1954–64.CrossRef Hernández-Mijares A, García-Malpartida K, Solá-Izquierdo E, Bañuls C, Rocha M, Gómez-Martínez MJ, Mármol R, Víctor VM. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med. 2010;7(5):1954–64.CrossRef
24.
go back to reference Li H, Kong XB, Zhang HL, Wu J. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular diseases. J Sex Med. 2011;8(4):1260.CrossRef Li H, Kong XB, Zhang HL, Wu J. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular diseases. J Sex Med. 2011;8(4):1260.CrossRef
25.
go back to reference Matsuda K, Ruff A, Morinelli TA, Mathur RS, Halushka PV. Testosterone increases thromboxane A2 receptor density and responsiveness in rat aortas and platelets. Am J Physiol. 1994;267(3 Pt 2):H887–93.PubMed Matsuda K, Ruff A, Morinelli TA, Mathur RS, Halushka PV. Testosterone increases thromboxane A2 receptor density and responsiveness in rat aortas and platelets. Am J Physiol. 1994;267(3 Pt 2):H887–93.PubMed
26.
go back to reference Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91(11):2742–7.CrossRef Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91(11):2742–7.CrossRef
27.
go back to reference Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14(5):701–6.CrossRef Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14(5):701–6.CrossRef
28.
go back to reference Ozata M, Oktenli C, Bingol N, Ozdemir IC. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res. 2001;9(11):662–7.CrossRef Ozata M, Oktenli C, Bingol N, Ozdemir IC. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res. 2001;9(11):662–7.CrossRef
29.
go back to reference Wong Long, Chen Hong-Mei, Lai Shui-Qing, Yang Hua-Zhang, Kuang Jian, Pei Jian-Hao. Effects of sulfonylurea as initial treatment on testosterone of middle-aged men with type 2 diabetes: a 16-week, pilot study. J Diabetes Investig. 2015;6(4):454–9.CrossRef Wong Long, Chen Hong-Mei, Lai Shui-Qing, Yang Hua-Zhang, Kuang Jian, Pei Jian-Hao. Effects of sulfonylurea as initial treatment on testosterone of middle-aged men with type 2 diabetes: a 16-week, pilot study. J Diabetes Investig. 2015;6(4):454–9.CrossRef
30.
go back to reference Sniderman AD, Thanassoulis G. Do statins lower testosterone and does it matter? BMC Med. 2013;28(11):58.CrossRef Sniderman AD, Thanassoulis G. Do statins lower testosterone and does it matter? BMC Med. 2013;28(11):58.CrossRef
31.
go back to reference Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68(3):314–29.CrossRef Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68(3):314–29.CrossRef
32.
go back to reference Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537–41.CrossRef Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537–41.CrossRef
33.
go back to reference Nadal JF, Gutiérrez PC. Type 2 diabetes mellitus and cardiovascular risk factors: is comprehensive treatment required? Med Clin (Barc). 2013;141(Suppl 2):7–13.CrossRef Nadal JF, Gutiérrez PC. Type 2 diabetes mellitus and cardiovascular risk factors: is comprehensive treatment required? Med Clin (Barc). 2013;141(Suppl 2):7–13.CrossRef
Metadata
Title
Is a Previously or Currently Reduced Testosterone Level in Male Patients with Type 2 Diabetes Mellitus a Risk Factor for the Development of Coronary Artery Disease? A Systematic Review and Meta-analysis
Author
Feng Huang
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 3/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-018-0415-3

Other articles of this Issue 3/2018

Diabetes Therapy 3/2018 Go to the issue